Literature DB >> 1457828

Anti-sense transforming growth factor alpha oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line.

A M Sizeland1, A W Burgess.   

Abstract

Many carcinoma cells secrete transforming growth factor alpha (TGF alpha). A 23 base anti-sense oligonucleotide that recognizes the TGF alpha mRNA inhibits both DNA synthesis and the proliferation of the colon carcinoma cell line LIM 1215. The effects of the anti-sense TGF alpha oligonucleotide are reversed by epidermal growth factor (EGF) at 20 ng/ml. When the LIM 1215 cells are grown under serum free conditions, the anti-sense TGF alpha oligonucleotides have their greatest effects at high cell density (2 x 10(5) cells/cm2), indicating that the secreted TGF alpha is acting as an exogenous growth stimulus. In addition, at higher cell densities, the kinase activity of the EGF receptor is activated and the receptor is down-modulated. The cell density dependent activation of the EGF receptor is inhibited by the application of the antisense TGF alpha oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457828      PMCID: PMC275690          DOI: 10.1091/mbc.3.11.1235

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  45 in total

1.  Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors.

Authors:  R Brachmann; P B Lindquist; M Nagashima; W Kohr; T Lipari; M Napier; R Derynck
Journal:  Cell       Date:  1989-02-24       Impact factor: 41.582

2.  Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells.

Authors:  M T Keating; L T Williams
Journal:  Science       Date:  1988-02-19       Impact factor: 47.728

3.  Direct demonstration of an autocrine mechanism in EMS-induced, tumorigenic mutants of the growth factor-dependent hemopoietic cell line, FDC-P1.

Authors:  A F Wilks; R R Kurban; A R Dunn
Journal:  Growth Factors       Date:  1989       Impact factor: 2.511

4.  c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells.

Authors:  E V Prochownik; J Kukowska; C Rodgers
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

5.  Production of transforming growth factors by human colon cancer lines.

Authors:  R J Coffey; G D Shipley; H L Moses
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

6.  Purification and characterization of a novel transforming growth factor.

Authors:  J Halper; H L Moses
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

7.  Transformation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA.

Authors:  R Sasada; T Kurokawa; M Iwane; K Igarashi
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

8.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.

Authors:  F Cuttitta; D N Carney; J Mulshine; T W Moody; J Fedorko; A Fischler; J D Minna
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

9.  Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus.

Authors:  A Johnsson; C Betsholtz; C H Heldin; B Westermark
Journal:  Nature       Date:  1985 Oct 3-9       Impact factor: 49.962

10.  Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor.

Authors:  D Becker; C B Meier; M Herlyn
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

View more
  15 in total

Review 1.  Calcium, a Cell Cycle Commander, Drives Colon Cancer Cell Diffpoptosis.

Authors:  Ahmed A Abd-Rabou
Journal:  Indian J Clin Biochem       Date:  2016-03-30

2.  Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth.

Authors:  P Tang; S A Jasser; J C Sung; Y Shi; P A Steck; W K Yung
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

3.  Regulation of transforming growth factor alpha expression in a growth factor-independent cell line.

Authors:  G M Howell; L E Humphrey; B L Ziober; R Awwad; B Periyasamy; A Koterba; W Li; J K Willson; K Coleman; J Carboni; M Lynch; M G Brattain
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

Review 4.  Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Authors:  Toni M Brand; Mari Iida; Deric L Wheeler
Journal:  Cancer Biol Ther       Date:  2011-05-01       Impact factor: 4.742

5.  Gastrointestinal hormone mRNA expression in human colonic adenocarcinomas, hepatic metastases and cell lines.

Authors:  G Monges; P Biagini; J F Cantaloube; P De Micco; D Parriaux; J F Seitz; J R Delpero; J Hassoun
Journal:  Clin Mol Pathol       Date:  1996-06

Review 6.  The autocrine loop of TGF-alpha/EGFR and brain tumors.

Authors:  P Tang; P A Steck; W K Yung
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

7.  Theaflavin-3, 3'-digallate induces epidermal growth factor receptor downregulation.

Authors:  Hideya Mizuno; Yong-Yeon Cho; Feng Zhu; Wei-Ya Ma; Ann M Bode; Chung S Yang; Chi-Tang Ho; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-03       Impact factor: 4.784

8.  Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.

Authors:  T Laitala; H K Väänänen
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 9.  Growth control mechanisms in normal and transformed intestinal cells.

Authors:  A W Burgess
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

10.  Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.

Authors:  Aditi Pandya Martin; Anna Miller; Luni Emad; Mohammed Rahmani; Teneille Walker; Clint Mitchell; Michael P Hagan; Margaret A Park; Adly Yacoub; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2008-06-10       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.